Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-843-9003223
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
AEterna Zentaris (TSE:AEZ) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AEZ."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (TSE:AEZ) released its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.12. The biopharmaceutical company had revenue of $0.87 million for the quarter. View AEterna Zentaris' Earnings History.
When is AEterna Zentaris' next earnings date?
Has AEterna Zentaris been receiving favorable news coverage?
Press coverage about AEZ stock has trended very positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AEterna Zentaris earned a news sentiment score of 3.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Carolyn Egbert, Independent Chairman of the Board
- Michael Ward, President, Chief Executive Officer, Director
- James Clavijo, Chief Financial Officer (Age 52)
- Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
- Jude Dinges, Chief Commercial Officer, Senior Vice President (Age 58)
- Eckhard G. Gunther Ph.D., Vice President - Alliance Management
- Michael Teifel, Vice President - Non-Clinical Sciences
- John W. Sharkey Ph.D., Business Development Consultant (Age 60)
- Philip Allen Theodore, Corporate Secretary (Age 64)
- David A. Dodd, Director (Age 65)
How do I buy shares of AEterna Zentaris?
Shares of AEZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is AEterna Zentaris' official website?
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 315 Sigma Dr Ste 302D, SUMMERVILLE, SC 29486-7790, United States. The biopharmaceutical company can be reached via phone at +1-843-9003223.
MarketBeat Community Rating for AEterna Zentaris (TSE AEZ)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
